['aml', 'relapse']
['chidamide plus dcag regimen']

        Inclusion Criteria:

          -  Men and women whose age more than 18 and less than 59；

          -  Patients diagnosed as AML according to the 2008 WHO (WHO) myeloid malignant disease
             diagnosis standard;

          -  Patients who relapsed after remission or who can not achieve remission after at least
             two cycle of systemic therapy (including chemotherapy, hematopoietic stem cell
             transplantation, etc.);

          -  ECOG performance status 0-3;

          -  Expected survival time ˃ 3 months;

          -  Patients without serious hearts, lung, liver, kidney disease;

          -  Patients have not received radiotherapy, chemotherapy, targeted therapy or
             hematopoietic stem cell transplantation and other treatment within 4 weeks prior to
             the enrollment;

          -  Patients are able to understand and willing to sign informed consent.

        Exclusion Criteria:

          -  Patients who allergy to the study drug or the drug with similar chemical structure;;

          -  Pregnancy, lactation women and women of childbearing age who do not want to practice
             effective methods of contraception;

          -  Active infection;

          -  Drug abuse, long-term alcohol abuse so as to affect the results of the evaluation of
             patients;

          -  Patients with mental disorders or other conditions can not obtain informed consent,
             can not meet the requirements of the study treatment and procedures;

          -  Patients have clinical significant QTc interval prolongation history (male > 450ms.
             Female >470ms), ventricular heart had tachycardia (VT) and atrial fibrillation (AF),
             II degree heart block, myocardial infarction attack (MI) within 1 year prior to the
             enrollment, congestive heart failure (CHF), patients of coronary heart disease who
             have clinical symptoms and need drug treatment.

          -  Cardiac ultrasound showed that the diastolic pericardial fluid dark area width ˃ 10mm;

          -  Patients have received organ transplantation;

          -  Active bleeding

          -  Patients have new thrombosis, embolism, cerebral hemorrhage and other diseases or
             medical history of patients within 1 year prior to enrollment;

          -  The main organs of the surgery is less than 6 weeks;

          -  Bone marrow hyperplasia and WBC <2.0 * 10^9/L;

          -  Liver function abnormalities (total bilirubin > 1.5 times of upper limit of normal
             range , ALT / AST > 2.5 times of the upper limit of normal range or patients with
             liver involvement whose ALT / AST > 1.5 times of upper limit of normal range), renal
             anomalies (serum creatinine > 1.5 times of upper limit of normal value );

          -  Not suitable for the study according to investigator's assessment.
      